Key result
Higher plasma serotonin is linked to worse flow-mediated dilation in low-to-moderate risk patients.
Why the study?
The clinical relationships between plasma serotonin, sphingosine 1-phosphate, and vascular endothelial function in early atherosclerosis were not well understood.
Do plasma serotonin and S1P levels correlate with endothelial function in patients with early atherosclerosis?
Observational (n=49)
Do plasma serotonin and S1P levels correlate with endothelial function in patients with early atherosclerosis?
Plasma serotonin and S1P levels correlate with endothelial function and may serve as useful biomarkers in patients with low-to-moderate atherosclerotic risk.
Answers are grounded in this paper and cite their sources.
Plasma serotonin and S1P levels may reflect endothelial function in early atherosclerosis; leaves open their clinical utility pending prospective validation.
OBJECTIVES: Serotonin stored in platelets is released into plasma on aggregation and activation in atherosclerotic diseases. Sphingosine 1-phosphate (S1P) in plasma is mainly derived from red blood cells and is responsible for the production of nitric oxide in endothelial cells and protects vasculature. The purpose of this study was to investigate the plasma levels of serotonin, S1P, and their clinical relationships with vascular endothelial function in patients with early atherosclerosis. METHODS: Blood was withdrawn from patients with low-to-moderate risks of atherosclerotic diseases (n=49, 39 ± 7 years). Platelet-poor plasma was immediately centrifuged. Serotonin levels in plasma were measured with high-performance liquid chromatography. S1P levels in plasma were measured by high-performance liquid chromatography after fluorescent derivatization with o-phthaldialdehyde. Endothelial function was assessed by endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent dilation was measured by glycerol trinitrate-induced dilation using an ultrasound system. RESULTS: Plasma serotonin was inversely correlated with the FMD value (r=-0.287, P<0.05). Fourteen patients with dyslipidemia, who had not shown improvements after lifestyle modifications, were subsequently treated with rosuvastatin (2.5 mg/day). After 4 weeks of treatment, rosuvastatin improved lipid profiles. Rosuvastatin increased FMD, whereas glycerol trinitrate-induced dilation was unchanged. Notably, percentage decrease in plasma serotonin was inversely correlated with percentage increase in plasma S1P (r=-0.557, P<0.05). CONCLUSION: Plasma serotonin was inversely correlated with FMD and a decrease in plasma serotonin was inversely correlated with an increase in plasma S1P after statin treatment. The results suggested that plasma levels of serotonin and S1P may be useful for the assessment of endothelial function of patients with low-to-moderate risks of atherosclerotic diseases.
No takes yet. Share an insight, caveat, or question.
Sugiura et al. (2012) conducted an observational in early atherosclerosis (n=49). Plasma serotonin and S1P levels was evaluated on Correlation between plasma serotonin and flow-mediated dilation (FMD) (r=-0.287, p=<0.05). In patients with low-to-moderate atherosclerotic risk, plasma serotonin was inversely correlated with flow-mediated dilation (r=-0.287, P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: